bluuebunny/crossref_metadata_2025_split huggingface dataset:
1822-LB: Family Support for Diabetes Action (FAM-ACT) vs. Traditional Diabetes Management Education and Support—Randomized Comparative Effectiveness Trial
Authors: ROSLAND ANN-MARIE , PIATT GRETCHEN , KIEFFER EDITH C. , VALBUENA FELIX , PALMISANO GLORIA , DEVERTS DENISE J. , PEREZ STEPHANIE , YABES JONATHAN , LALAMA CHRISTINA M. , HEISLER MICHELE 
Published: June 2024

Introduction: Family support can be crucial to sustaining gains from diabetes self-management education/support (DSMES), especially for low SES Hispanic adults with diabetes (AWD). DSMES lacks structured approaches to engaging support persons (SP). Our objective was to determine the effectiveness of FAM-ACT, a DSMES program focused on AWD-SP dyads vs DSMES with individual AWD, both CHW-delivered and tailored to Hispanic AWD.
Methods: Adult patients with T2D and A1C ≥7.5% at an FQHC serving a Hispanic population were enrolled with an adult SP; dyads were randomized to FAM-ACT or DSMES, then invited to 6 sessions over 6 months. Each FAM-ACT session included SP training on supporting AWD diabetes management. AWD A1C was measured at baseline, 6 and 12 months. The primary outcome was 6-month change in A1C, analyzed using linear mixed models.
Results: Among 222 AWD-SP dyads enrolled, AWD were mean age 52 years (SD 10), 38% men, 82% preferred Spanish language, 39% had a high school degree or more. SPs were mean age 45 (SD 13), 47% were the AWD’s spouse/partner, 26% adult child, and 27% sibling/friend/other. AWD completed mean 3.8/6 sessions, and SP in FAM-ACT arm 2.7/6. In ITT analyses, A1C 6-month decline was greater in DSMES than FAM-ACT (-0.97% vs. -0.42%, p=0.06) but at 12 months, they were similar (DSMES -0.55%, FAM-ACT -0.65%, p=0.77). In Complier Average Causal Effect (CACE) analyses based on AWD and SP with at least average expected session attendance, FAM-ACT 6 month A1C decline was -1.32% vs DSMES -0.89%, p=0.59 and at 12 months FAM-ACT had sustained decline (-1.23% vs -0.47% DSMES, p=0.63).
Conclusion: FAM-ACT was less effective at lowering 6-month A1C than traditional DSMES among low SES Hispanic adults, however FAM-ACT A1C continued to improve 6 months after the program ended while traditional DSMES gains regressed. When supporters engaged with patients in FAM-ACT, AWD had clinically significantly larger improvements that were sustained.

Disclosure
A. Rosland: None. G. Piatt: None. E.C. Kieffer: None. F. Valbuena: None. G. Palmisano: None. S. Perez: None. J. Yabes: Other Relationship; Bayer Inc. M. Heisler: None.

Funding
National Institute of Diabetes and Digestive and Kidney Diseases (R01DK116733)
1861-LB: Efficacy and Safety of HRS9531, a Novel Dual GLP-1/GIP Receptor Agonist, in Obese Adults—A Phase 2 Trial
Authors: ZHAO LIN , ZHU DAN , LIU DEXUE , PAN TIANRONG , WANG DONGJI , HUI YUAN , LING HONGWEI , CAI HANQIN , ZENG MEIFANG , ZUO YUE , SUN YUQI , WANG YIKE , LI XIAOYING 
Published: June 2024

Introduction: HRS9531, a novel dual GLP-1 and GIP receptor agonist, has shown prominent efficacy in glycemic control and weight loss in phase 1 trials. This phase 2 study evaluated the efficacy and safety of HRS9531 in obese adults without diabetes.
Methods: In this randomized, double-blind, placebo-controlled phase 2 study, 249 Chinese adults with a BMI of 28-40 kg/m2 were randomized 1:1:1:1:1 to receive once-weekly subcutaneous injections of HRS9531 (1.0 mg, 3.0 mg, 4.5 mg, and 6.0 mg) or placebo for 24 weeks (24W). The primary endpoint was the percentage change in body weight at W24.
Results: The least-squares mean percentage change in body weight from baseline at W24 was -5.4% (95% CI -7.3% to -3.5%), -13.4% (-15.2% to -11.5%), -14.0% (-15.9% to -12.1%), and -16.8% (-18.8% to -14.9%) in the 1.0 mg, 3.0 mg, 4.5 mg, and 6.0 mg groups, respectively, compared to -0.1% (-2.1% to 1.8%) in the placebo group (P&lt;0.0001 for all comparisons with placebo). The proportion of participants achieving ≥5% body weight reduction was 52.0%, 88.2%, 92.0%, 91.8%, and 10.2%, respectively. Additionally, HRS9531 outperformed placebo in lowering blood pressure, improving glycemic control, and reducing triglyceride levels. The least-squares mean changes from baseline to W24 in systolic blood pressure ranged from -4.46 to -8.33 mmHg in the HRS9531 groups (placebo: -0.41 mmHg) and in the waist circumference ranged from -5.14 to -12.73 cm in the HRS9531 groups (placebo: -1.82 cm). Most adverse events (AEs) were mild or moderate in severity, and the most common AEs were nausea, diarrhea, decreased appetite, and vomiting, occurring primarily during dose escalation. No serious AEs were treatment-related and no participants discontinued treatment due to treatment-related AEs.
Conclusion: HRS9531 effectively reduced body weight, blood pressure, blood glucose, and triglycerides, with a favorable safety profile. These data support further clinical development of HRS9531 for obesity treatment.

Disclosure
L. Zhao: None. D. Zhu: None. D. Liu: None. T. Pan: None. D. Wang: None. Y. Hui: None. H. Ling: None. H. Cai: None. M. Zeng: Employee; Jiangsu Hengrui Pharmaceuticals Co., Ltd. Y. Zuo: Employee; Jiangsu Hengrui Pharmaceuticals Co., Ltd. Y. Sun: Employee; Jiangsu Hengrui Pharmaceuticals Co., Ltd. Y. Wang: Employee; Jiangsu Hengrui Pharmaceuticals Co., Ltd. X. Li: None.

Funding
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
1871-LB: Phase 1 Topline Safety, Efficacy, and Pharmacokinetics of Oral Ecnoglutide
Authors: ZHU ZHIYI , LI YAO , WANJUN GUO , ZHENG QING , DENG JIANHUI , ADEGBITE ERIC , ROSS STEPHEN , TELUSCA LIBNIR , JONES CATHERINE L. , FENAUX MARTIJN , XU SUSAN , JUNAIDI MOHAMMED K. 
Published: June 2024

Introduction & Objective: Ecnoglutide is a cAMP-biased, long-acting GLP-1RA being developed for the treatment of type 2 diabetes mellitus and obesity. Oral ecnoglutide (XW004) is formulated with an absorption enhancer, PNAC (T2026). The objective of this study was to evaluate the safety and tolerability of oral ecnoglutide in healthy adults.
Methods: We conducted a randomized, double-blind, placebo-controlled Phase 1 study in healthy (Cohorts 1 to 3) and healthy obese (Cohort 4) adults. Participants (n = 56) were randomized to receive oral ecnoglutide at target doses of 7, 15, or 30 mg QD for up to 6 weeks, with dose escalation.
Safety, tolerability, PK, and body weight were assessed. The results of Cohorts 1 to 4 are presented, the study is ongoing to evaluate additional dosing schemes.
Results: Oral ecnoglutide was generally safe and well tolerated. The most common AEs were mild to moderate gastrointestinal events that occurred during dose escalation. There were no serious AEs. One participant experienced a Grade 3 AE of diarrhea that led to study drug discontinuation.
At baseline, participants had a mean BMI of 25.8 to 26.1 kg/m2 (Cohorts 1 to 3) and 32.9 kg/m2 (Cohort 4). At end of treatment, participants in Cohorts 1 to 3 receiving up to 7, 15, or 30 mg QD oral ecnoglutide for 2 weeks had body weight change from baseline of -3.63, -3.38, and -6.55%, respectively vs -0.85% for placebo. Participants in Cohort 4 receiving up to 30 mg QD for 6 weeks had a body weight reduction of -6.76% vs -0.85% for placebo.
At steady state, oral ecnoglutide 30 mg QD resulted in a plasma AUC0-24h of 12,470 h*ng/mL and calculated weekly AUC 0-168h of 87,290 h*ng/mL.
Conclusion: Oral ecnoglutide was safe and well tolerated and resulted in pronounced weight loss after 6 weeks of dosing. Improved oral bioavailability enables a daily dose of 30 mg oral ecnoglutide to match or exceed the plasma exposure of weekly subcutaneous GLP-1 analogs. Oral ecnoglutide has a potential to be a best-in-class oral GLP-1RA.

Disclosure
Z. Zhu: None. Y. Li: Employee; Sciwind Biosciences. G. Wanjun: Employee; Sciwind Biosciences. Q. Zheng: Employee; Sciwind Biosciences. J. Deng: Employee; Sciwind Biosciences. E. Adegbite: Employee; Sciwind Biosciences. S. Ross: None. L. Telusca: None. C.L. Jones: Employee; Sciwind Biosciences. M. Fenaux: None. S. Xu: None. M.K. Junaidi: None.

Funding
Sciwind Biosciences
1910-LB: Disparities in Initiation of Continuous Glucose Monitoring and Impact on Glycemic Control in Children and Adolescents with Type 1 Diabetes
Authors: BORBJERG METTE , KVIST ANNIKA V. , MEHTA KALA , EJSKJAER NIELS , WONG JENISE C. 
Published: June 2024

Introduction & Objective: The American Diabetes Association recommends continuous glucose monitoring (CGM) for all people with type 1 diabetes (T1D) as early as the time of diagnosis. CGM has been associated with reductions in HbA1c, and it has been recommended that CGM should be initiated within 12 months of diagnosis. We aimed to determine the impact of insurance and race/ethnicity on the timing of CGM initiation in children with T1D and to compare glycemic control in those initiating CGM within six months of diagnosis compared to later initiation.
Methods: Children up to age 21 years followed at UCSF Benioff Children’s Hospital diagnosed with T1D between February 2015 and September 2021 were included (n = 270) and grouped according to time of CGM initiation. Analysis of insurance and race/ethnicity was done using one-way ANOVA or Kruskal Wallis H-test. T-test and Wilcoxon test were performed to compare early and late CGM initiation.
Results: The median time from T1D diagnosis to CGM initiation was 6 months for publicly insured individuals compared to 2 months for privately insured individuals (p-value &lt; 0.001), similar differences were found between individuals of racial or ethnic minority (minority) groups and individuals identified as white, non-Hispanic. Median HbA1c was 7.5% for children with time-of-initiation &lt; 6 months; 8.4% for children with time-of-initiation &gt; 6 months (p-value &lt; 0.001).
Conclusion: Publicly insured children and children of minority groups experience delays in starting recommended T1D treatment with CGM, with a longer time-to-initiation as compared to privately insured children and white, non-Hispanic children. This is of clinical importance, as more optimal glycemic control has been associated with earlier initiation of CGM. Barriers to CGM initiation may result in less optimal glycemic control for publicly insured children and children of minority groups with diabetes.

Disclosure
M. Borbjerg: None. K. Mehta: None. N. Ejskjaer: None. J.C. Wong: Research Support; Dexcom, Inc., Tandem Diabetes Care, Inc., Abbott.
1981-LB: Modeling the Impact of Semaglutide 2.4 mg in U.S. Patients with Atherosclerotic Cardiovascular Disease and BMI ≥27 kg/m2
Authors: FAURBY MADS , NANNA MICHAEL G. , TOLIVER JOSHUA C. , DOAN QUAN V. , HENRY ALASDAIR D. , SCASSELLATI SFORZOLINI THOMAS , LEVINE ALINA , FABRICATORE ANTHONY , HOUSHMAND-OEREGAARD AZADEH S. , MARIE NAVAR ANN 
Published: June 2024

The SELECT trial demonstrated a 20% risk reduction in major adverse cardiovascular events (MACE) with semaglutide 2.4 mg in adults with atherosclerotic cardiovascular disease (ASCVD) and overweight/obesity (BMI ≥27 kg/m2). We aimed to quantify the potential population impact of this treatment in the US. National Health and Examination Survey (NHANES) data were used to characterize the US population meeting SELECT trial criteria: BMI ≥27 kg/m2, age ≥45 years, ASCVD, and no diabetes, with the number of potential treatment candidates determined using 2023 census projections. The 10-year rate of recurrent MACE events was estimated based on the SMART2 risk calculator. The potential treatment effect of semaglutide 2.4 mg on the number of MACE events in this population was estimated using results from the SELECT trial. As of 2023, 6,161,981 US adults met SELECT inclusion criteria (mean age 67.2 ± 9.9 years, 43.6% female, mean BMI 32.6 ± 5.0 kg/m2). Based on SMART2, an estimated 2,529,310 individuals (41.0%) will experience at least one MACE event in the next 10 years, with the total number of events estimated at 3,064,993. Of these, 497,631 MACE events could be avoided with semaglutide 2.4 mg treatment (Table). The possible therapeutic impact of semaglutide 2.4 mg on eligible US adults is substantial, with the potential to prevent nearly half a million CV events and deaths over the next 10 years.

Disclosure
M. Faurby: Employee; Novo Nordisk. M.G. Nanna: Consultant; Merck & Co., Inc., HeartFlow, Inc. J.C. Toliver: Employee; Novo Nordisk. Q.V. Doan: Consultant; Novo Nordisk, Daiichi Sankyo, Akebia Therapeutics, Inc., AbbVie Inc. A.D. Henry: Consultant; Novo Nordisk. T. Scassellati Sforzolini: Consultant; Novo Nordisk. A. Levine: Consultant; Novo Nordisk. A. Fabricatore: Employee; Novo Nordisk. Stock/Shareholder; Novo Nordisk. A.S. Houshmand-Oeregaard: Employee; Novo Nordisk. Stock/Shareholder; Eli Lilly and Company, Novo Nordisk A/S. A. Navar: Consultant; ESPERION Therapeutics, Inc. Research Support; ESPERION Therapeutics, Inc. Consultant; Amgen Inc. Research Support; Amgen Inc., Bristol-Myers Squibb Company. Consultant; Bristol-Myers Squibb Company, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Bayer Inc., Novartis Pharmaceuticals Corporation, Novo Nordisk, Pfizer Inc., New Amsterdam, Boehringer-Ingelheim, Eli Lilly and Company, Silence Therapeutics.

Funding
Novo Nordisk, Inc.
2071-LB: Reduced Risk of Obesity-Related Cancers with Real-World Weight Loss
Authors: ALKWATLI KENDA , XIAO HUIJUN , MARIAM ARSHIYA , PANTALONE KEVIN M. , ROTROFF DANIEL M. 
Published: June 2024

Objective: To assess whether real-world weight loss is associated with a modified risk of developing cancer.
Methods:A retrospective observational study was conducted using the electronic health record at Cleveland Clinic (1/1/00-12/31/22).
The primary endpoint was the development of 13 obesity-related cancers, and the secondary endpoint was the occurrence of 17 other types of cancer. The association between the % change in body mass index (BMI) 3, 5, and 10 year intervals prior to cancer diagnosis (for cases) vs. controls for each cancer endpoint was assessed using logistic regression models.
Results:A total of 105,489 patients:100,162 controls and 5327 cases were identified. The % female was 43% and 52%, the % White was 84% and 78%, and median age (years) was 62 and 53, among cases and controls, respectively. Median BMI at censoring (kg/m2.) was 34.3 for cases and 34.5 for controls.
Our results show reduced risk of developing obesity-related cancers with weight loss at 3 years (OR 0.99, 95%CI [0.984, 0.996]) and 5 years (OR 0.989,95% CI [0.983-0.995]), and for other types of cancer for all time intervals (ORs&lt;1, P &lt;0.001) (Figure 1a). The risk was reduced for renal cell carcinoma (3 years), multiple myeloma (10 years), and endometrial cancer (3& 5years) among primary cancer endpoints (P&lt;0.05) (Figure 1b).
Conclusion:A decrease in risk of developing obesity-related cancers and other types of cancer was associated with real-world weight loss.

Disclosure
K. Alkwatli: None. H. Xiao: None. A. Mariam: None. K.M. Pantalone: Speaker's Bureau; AstraZeneca. Consultant; AstraZeneca. Board Member; Bayer Inc. Research Support; Bayer Inc. Speaker's Bureau; Corcept Therapeutics. Consultant; Corcept Therapeutics, Diasome, Eli Lilly and Company, Merck & Co., Inc. Speaker's Bureau; Merck & Co., Inc. Research Support; Merck & Co., Inc. Consultant; Novo Nordisk. Research Support; Novo Nordisk. Speaker's Bureau; Novo Nordisk. Research Support; Twin Health. Consultant; Sanofi. D.M. Rotroff: Consultant; Novo Nordisk. Research Support; Bayer Inc.
366-P: Mean Blood Glucose–Independent Racial Disparity in HbA1c and Higher Risk for Severe Hypoglycemia Is Evident among Participants in the Diabetes Control and Complications Trial
Authors: CHALEW STUART , MCCARTER ROBERT J. 
Published: June 2024

Introduction: HbA1c target levels are often used as a treatment goal for patients with diabetes. Many recent studies indicate that HbA1c overestimates mean blood glucose (MBG) among Non-Hispanic Black (NHB) patients compared to Non-Hispanic White (NHW). We hypothesized that this disparity could be associated with greater risk of hypoglycemia in NHB patients especially where management is primarily based on a treat to HbA1c target. To assess this possibility we analyzed multiyear repeated-measures data from the Diabetes Control and Complications Trial (DCCT).
Methods: Publicly available DCCT data was analyzed using mixed effects general linear modeling to evaluate the differences in HbA1c vs MBG for NWB (n=29) and NHW (n=1391) patients accounting for within patient correlation of HbA1c as well as MBG across multiple assessments. The model also controlled for age, diabetes duration, visit year and quarter, body mass index, study group and stratum. as well as interactive and nonlinear effects. Risk for severe hypoglycemia by ethnicity was separately determined.
Results: Over the course of the DCCT, NHB pts had higher HbA1c than NHW patients at any given level of MBG, with greatest difference at lower MBG levels (p=0.001). The difference between groups in HbA1c by MBG adjusted for covariables was 0.51 at MBG of 150 mg/dl (p&lt;0.03) and 0.39 at MBG of 450 mg/dl (p=0.09) Severe hypoglycemia increased with decreasing HbA1c. Relative risk for severe hypoglycemia for NHB was 1.92 compared to NHW (p=0.02).
Conclusions: Among patients in the DCCT, HbA1c overpredicted MBG among NHB and was associated with greater risk for severe hypoglycemia. Predominant reliance on target HbA1c for management of diabetes may contribute to higher risk for hypoglycemia among NHB patients.

Disclosure
S. Chalew: None. R.J. McCarter: None.

Funding
National Intitutes of Health (1R21DK118643-O1A1)
920-P: Sodium–Glucose Cotransporter 2 Inhibitor Use and Risk of Dementia and Parkinson’s disease among Patients with Type 2 Diabetes—A Longitudinal, Nationwide, Population-Based Cohort Study
Authors: KYUNG KIM HAE , BIESSELS GEERT J. , YU MINHEUI , BAE JIHOON , CHOI ARIM , LEE MINYOUNG 
Published: June 2024

The efficacy of sodium-glucose cotransporter 2 inhibitor (SGLT2i) in neurologic disorders is not well-established. This study aimed to investigate the association of SGLT2i use with risks of incident dementia and Parkinson’s disease (PD) in patient with type 2 diabetes. Subjects aged ≥ 40 years, diagnosed with type 2 diabetes, and who started antidiabetic drugs from 1 September 2014 and 31 December 2019 were evaluated, using the National Health Insurance Service Database. Propensity score matching (1:1; SGLT2i to other oral antidiabetic drugs [OAD]) produced a cohort of 358,862. Primary outcomes were a composite of dementia from any cause (Alzheimer’s disease [AD], vascular dementia [VaD], and other dementia) and PD. From the 358,862 participants analyzed (mean age, 57.8 years; 57.9% male), 6,837 incident dementia or PD events occurred. Overall, use of SGLT2i was associated with a 22% lower risk for the composite of dementia from any cause and PD than use of other OADs (adjusted HR [aHR], 0.78 [95% CI 0.73─0.83]) with a 6-month lag period. Regarding the individual endpoints, SGLT2i use was associated with reduced risks for AD (aHR, 0.81 [95% CI 0.76─0.87]), VaD (aHR, 0.69 [95% CI 0.60─0.78]), and PD (aHR, 0.80 [95% CI 0.69─0.91]). In this nationwide population-based cohort study, SGLT2i use significantly reduced the risks for dementia and PD in patients with type 2 diabetes independent of various factors including comorbidities and bioclinical parameters.

Disclosure
H. Kim: None. G.J. Biessels: None. M. Yu: None. J. Bae: None. A. Choi: None. M. Lee: Other Relationship; JW Pharmaceutical Corporation, Boryung Corporation, Eli Lilly and Company, Merck Sharp & Dohme Corp., HK inno.N, Servier Korea, Handok Inc., Daewoong Pharmaceutical, KUKJE PHARM CO., LTD, GC Biopharma Corporation.

Funding
Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (HR22C141104)2); 'SENTINEL (Severance Endocrinology daTa scIeNcE pLatform)’ program funded by the 2020 Research fund of Department of Internal Medicine, Severance Hospital; Sung-Kil Lim Research Award (4-2018-1215; DUCD000002); Yonsei University College of Medicine (6-2020-0155)
Survey and Present Status of Soybean Diseases in Central India
Authors: Amrate Pawan K. 
Published: June 2024

The experiment was conducted during kharif (July to September), 2018 and 2019 at J.N.K.V.V., Jabalpur, Madhya Pradesh, India to study the current status of soybean diseases in central Indian conditions. A fixed plot survey of nine soybean varieties was carried out at three different growth stages i.e. seedling stage (V2-V3), early reproductive stage (R2-R4) and late reproductive stage (R5-R7). The study found that soybean varieties were infected with fourteen diseases in the current cultivation scenario. Collar rot (0.0–4.88%), root rot (0.63–4.13%) and soybean mosaic (0.0–8.38%) was initially noticed at the seedling stage in the second and third week of July. At early reproductive stages, yellow mosaic (0.0–35.0%), bacterial pustule (0.0–8.0%), and anthracnose (0.00–35.13%) were dominating diseases in the third week of July (yellow mosaic) to the first week of August (bacterial pustule). At late reproductive stage (first week of August to the third week of September), the average range of incidence of aerial blight (1.25–30.63%), frog eye leaf spot (0.75–21.13%), charcoal rot (0.0–65.13%), Pod blight (0.0–10.63%), myrothesium leaf spot (0.0–2.88%), target leaf spot (0.0–6.13%) and alternaria leaf spot (0.0–5.0%) were varied from low to high. At maturity, the soybean seeds were infected with purple seed stain (0.38–7.0%). Through incidence and varietal influence patterns, charcoal rot, yellow mosaic, Anthracnose/pod blight, aerial blight, and frog eye leaf spot could be considered significant concerns for soybean cultivation in this region.
Analyzing Determinants of Mobile Banking Adoption in the Context of Indonesian Sharia Banks: A UTAUT 3 Framework
Authors: Indana Rifaatul , Atika Rindi 
Published: June 2024

Mobile Banking become one of the main components in digital strategy. Bank Syariah Indonesia also provides BSI services Mobile. BSI usersMobile continues to increase but not yet comparable to the total number of BSI customers. This study aims to determine the factors that influence behavioral intention in using Mobile Banking BSI. In this study applying quantitative methods and using the theory of UTAUT-3. This study took a sample of Islamic banking students in Yogyakarta. The research was analyzed using the SEM approach (Structural Equation Model) PLS based (Partial Least Square). The statistical test results show that the Facilitating Conditions (Facilitating Conditions) and Price Value (Price Value) influencing intention in usage behavior Mobile Banking BSI to Islamic Banking students in Yogyakarta. Keywords:UTAUT 3, Mobile Banking, Behavioral Intentions